SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000899243-20-010117
Filing Date
2020-04-03
Accepted
2020-04-03 16:07:03
Documents
1
Period of Report
2020-04-01

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 7887
  Complete submission text file 0000899243-20-010117.txt   9304
Mailing Address 171 OYSTER POINT BLVD, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650741-7700
Global Blood Therapeutics, Inc. (Issuer) CIK: 0001629137 (see all company filings)

IRS No.: 274825712 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences

Mailing Address C/O GLOBAL BLOOD THERAPEUTICS 171 OYSTER POINT BLVD, STE. 300 SAN FRANCISCO CA 94080
Business Address
JOHNSON DAVID LEE (Reporting) CIK: 0001733883 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37539 | Film No.: 20773379